Daraxonrasib in pancreatic cancer: DIRAS1 (198) is virtually adjacent to Lucas number 199 (L8; 99.5% fit), and DIRAS3 (229) is within 1.7% of Fibonacci number 233 (F13). This fits Geier's programme very well!
Daraxonrasib in pancreatic cancer: DIRAS1 (198) is virtually adjacent to Lucas number 199 (L8; 99.5% fit), and DIRAS3 (229) is within 1.7% of Fibonacci number 233 (F13). This fits Geier's programme very well! Yours Stefan Geier, Haidholzen https://blog.dana-farber.org/.../ras-inhibitors.../... Addita: I. Evaluating the Proposed Convergence of Daraxonrasib Pharmacology, DIRAS Protein Lengths, and Geier's Programme Abstract Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by oncogenic mutations in the RAS signaling pathway. Recently, daraxonrasib (Rasonque), a first-in-class multi-selective RAS(ON) tri-complex inhibitor, demonstrated significant therapeutic efficacy in late-stage PDAC clinical trials and received approval for metastatic disease. Concurrently, mathematical frameworks such as "Geier's Programme" attempt to map physical and biological observables onto integer series derived from the Golden Ratio ( $\Phi$ ), specifically Fibonacci number...